RNTCP Launches Cat IV (DOTS Plus) treatment for Multi-Drug Resistant TB

Multi-drug resistant Tuberculosis (MDR-TB) is defined as resistance of Mycobacterium tuberculosis to Rifampiocin and Isoniazid, two of the most effective anti-tubercular drugs for treatment of Tuberculosis. Drug resistant tuberculosis has frequently been encountered in India and its presence has been known virtually from the time anti-tubercular drugs were introduced for the treatment of TB. There have been a number of reports on drug resistance in India including state level Drug resistance surveillance (DRS) surveys conducted in
Gujarat and Maharashtra. Data from these studies have found MDR-TB levels of about 3% in new cases and 12%-17% in re-treatment cases. Although the level of MDR-TB in the community is low in relation to percentages and proportions it translates into large absolute
numbers. To address this issue the Revised National Tuberculosis Control Programme (RNTCP) has initiated the DOTS Plus strategy for appropriate management of MDR TB patients and to prevent the propagation and dissemination of MDR-TB.

Download here

1. Guidelines

2. Status Report

No comments yet.

Leave a Reply